CD3 x tumor antigen x immune checkpoint (multi-specific)

Class

T-cell-engaging multi-specific antibody

Pathway

T-cell redirection to tumor antigen-positive cells

This mechanism describes a multi-specific antibody engineered to bind three distinct targets simultaneously: CD3, a signaling component of the T-cell receptor complex present on essentially all T lymphocytes; a tumor-associated antigen expressed preferentially on malignant cells; and an immune checkpoint protein, one of the receptors or ligands that normally restrains T-cell activity to prevent excessive immune responses. By engaging CD3, the molecule physically links T cells to tumor cells, forming a synthetic contact analogous to the immune synapse that occurs during natural immune recognition, and triggers the T cell to release cytotoxic molecules that kill the attached tumor cell independent of the T-cell receptor's usual antigen specificity. Simultaneously blocking or modulating a checkpoint pathway at that same site addresses a separate problem: tumors frequently exploit checkpoint signaling to suppress the very T cells being recruited. Combining tumor-antigen-restricted T-cell redirection with checkpoint modulation in a single molecule aims to produce more durable cytotoxic activity than either approach alone. This general strategy is relevant across many solid and hematologic cancers where tumor cells both express identifiable surface antigens and actively suppress local immune activity through checkpoint expression.